Source: Annals of hematology. Unidade: FM
Subjects: DOENÇA CRÔNICA, LEUCEMIA MIELOIDE, SOBREVIDA, ESTUDOS MULTICÊNTRICOS, ESTUDOS RANDOMIZADOS
ABNT
FERREIRA, Amanda Pifano Soares et al. Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and the early molecular response. Annals of hematology, v. 102, n. 7, p. 1761-1771, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54584. Acesso em: 04 out. 2024.APA
Ferreira, A. P. S., Seguro, F. S., Abdo, A. R. N., Santos, F. M., Maciel, F. V. R., Nardinelli, L., et al. (2023). Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and the early molecular response. Annals of hematology, 102( 7), 1761-1771. doi:10.1007/s00277-023-05189-3NLM
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Rego EM, Rocha VG. Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and the early molecular response [Internet]. Annals of hematology. 2023 ; 102( 7): 1761-1771.[citado 2024 out. 04 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54584Vancouver
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Rego EM, Rocha VG. Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and the early molecular response [Internet]. Annals of hematology. 2023 ; 102( 7): 1761-1771.[citado 2024 out. 04 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54584